Author

Tomohiro Sakamoto

Tottori University Hospital - Cited by 899 - lung cancer - precision medicine - clinical trial

Biography

Division of Cardiology, Cardiovascular Center, Saiseikai Kumamoto Hospital....RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.
Title
Cited by
Year
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...New England Journal of Medicine 383 (9), 813-824, 2020202
507
2020
PL02. 08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers
A Drilon, G Oxnard, L Wirth, B Besse, O Gautschi, SWD Tan, H Loong, ...Journal of Thoracic Oncology 14 (10), S6-S7, 2019201
96
2019
Phase II study of tepotinib in NSCLC patients with METex14 mutations.
PK Paik, R Veillon, AB Cortot, E Felip, H Sakai, J Mazieres, F Griesinger, ...Journal of Clinical Oncology 37 (15_suppl), 9005-9005, 2019201
79
2019
DNA-PK inhibition by NU7441 enhances chemosensitivity to topoisomerase inhibitor in non-small cell lung carcinoma cells by blocking DNA damage repair
M Yanai, H Makino, B Ping, K Takeda, N Tanaka, T Sakamoto, ...Yonago Acta Medica 60 (1), 9, 2017201
32
2017
Multiplex gene‐panel testing for lung cancer patients
Y Yatabe, K Sunami, K Goto, K Nishio, N Aragane, S Ikeda, A Inoue, ...Pathology international 70 (12), 9-931, 2020202
21
2020
Nivolumab‑induced cholangitis in patients with non‑small cell lung cancer: Case series and a review of literature
H Izumi, M Kodani, J Kurai, K Takeda, R Okazaki, K Yamane, Y Teruya, ...Molecular and Clinical Oncology 11 (5), 439-446, 202
19
2019
Japanese lung cancer society guidelines for stage IV NSCLC with EGFR mutations
K Ninomiya, S Teraoka, Y Zenke, H Kenmotsu, Y Nakamura, Y Okuma, ...JTO Clinical and Research Reports 2 (1), 100107, 2021202
18
2021
Food-borne botulism in Japan in March 2012
Y Momose, H Asakura, M Kitamura, Y Okada, Y Ueda, Y Hanabara, ...International Journal of Infectious Diseases 24, 20-22, 2014201
15
2014
Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic …
Y Tamiya, Y Zenke, S Matsumoto, N Furuya, T Sakamoto, T Kato, ...Journal of Clinical Oncology 38 (15_suppl), 9589-9589, 2020202
14
2020
A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after …
T Sakamoto, M Kodani, M Takata, H Chikumi, M Nakamoto, S Nishii-Ito, ...International Journal of Oncology 46 (4), 1473-1480, 2015201
12
2015
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
H Sakai, M Morise, T Kato, S Matsumoto, T Sakamoto, T Kumagai, ...Japanese Journal of Clinical Oncology 51 (8), 1261-1268, 2021202
11
2021
An onion farmer with a case of hypersensitivity pneumonitis caused by Aspergillus niger
T Sakamoto, A Yamasaki, Y Funaki, T Harada, R Okazaki, Y Hasegawa, ...Respiratory medicine case reports 23, 60-62, 2018201
10
2018
Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non–small cell lung cancer …
N Haratake, H Hayashi, M Shimokawa, Y Nakano, K Azuma, M Oki, K Ota, ...Clinical lung cancer 23 (3), e257-e263, 2022202
10
2022
A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer
M Takata, H Chikumi, K Matsunami, M Kodani, T Sakamoto, K Hashimoto, ...Oncology Reports 33 (3), 1040-1048, 2015201
9
2015
Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer
H Izumi, A Yamasaki, K Takeda, M Kodani, H Touge, N Tanaka, M Yanai, ...Lung Cancer 122, 200-205, 2018201
9
2018
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR …
S Ito, T Igishi, M Takata, Y Ueda, S Matsumoto, M Kodani, K Takeda, ...International Journal of Oncology 44 (3), 85-92, 2014201
6
2014
Frequency of Epidermal Growth Factor Receptor mutation in smokers with lung cancer without pulmonary emphysema
K Takeda, A Yamasaki, T Igishi, Y Kawasaki, S Ito-Nishii, H Izumi, ...Anticancer Research 37 (2), 75-771, 2017201
6
2017
Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
K Park, E Felip, R Veillon, A Cortot, J Mazieres, H Sakai, N Reinmuth, ...Annals of Oncology 30, ix22-ix23, 2019201
5
2019
Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases
H Izumi, T Igishi, A Yamasaki, K Takeda, M Yanai, N Tanaka, T Sakamoto, ...Molecular and Clinical Oncology 7 (6), 1000-1004, 2017201
5
2017
Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study
Tepotinib in NSCLC patients with METex1 mutations: interim results from the phase II VISION studyH Sakai, R Veillon, AB Cortot, E Felip, J Mazieres, M Morise, T Sakamoto, ...Annals of Oncology 30, vi108-vi109, 2019201
4
2019

Referred From: https://scholar.google.com/citations?user=N2Q4qTMAAAAJ&hl=en

Cited by
Citations 899
h-index 11
i10-index 13
Recommended Journals
Open Access Journals